You might also like
Revolution Medicines, Inc. (RVMD) is a clinical-stage precision oncology company specializing in the development of targeted therapies for RAS-addicted cancers. The company leverages advanced drug discovery technologies to create small molecules that address unconventional binding sites in cancer cells. RVMD's offerings include a pipeline of RAS(ON) inhibitors and companion inhibitors, designed for use as monotherapies or in combination regimens to combat genetic drivers and resistance mechanisms in cancer.
-
RAS(ON) Inhibitors - Develops small molecules that directly bind to active, GTP-bound RAS variants, suppressing cancer cell growth and survival. Includes clinical-stage candidates such as RMC-6236, RMC-6291 (G12C), and RMC-9805 (G12D), as well as preclinical candidates like RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C).
-
RAS Companion Inhibitors - Targets key nodes in the RAS pathway or associated pathways to enhance the efficacy of RAS(ON) inhibitors, primarily for combination treatment strategies.
-
Combination Therapies - Evaluates RAS(ON) inhibitors in combination regimens, including doublet therapies with other investigational drugs, to address adaptive resistance mechanisms in cancer.
- Can you explain the specific reasons behind the delay in initiating the Phase III registrational study for RMC-6236 in non-small cell lung cancer, and what challenges remain before regulatory alignment can be achieved?
- Given that you initiated the Phase III trial for pancreatic cancer but not yet for lung cancer, can you discuss the differences in data or strategic considerations that have led to the divergence in timelines between these two programs?
- With your cash runway projected to fund operations into 2027, can you clarify what is included in your financial projections, specifically how potential future pivotal trials beyond the two disclosed Phase III second-line studies are factored into your probability-adjusted model?
- In the RAS(ON) inhibitor doublet study combining RMC-6236 with RMC-6291, can you provide more details on the patient population, including prior treatments and tumor types, and what specific qualitative evidence are you seeking to assess the combination's effectiveness over monotherapy?
- Regarding your clinical collaboration with Tango Therapeutics, what strategic considerations led you to choose their PRMT5 inhibitor over other programs, and how does this collaboration align with your broader combination strategy for RMC-6236?